$SILO
Silo Pharma, Inc. Stock $silo

$silo Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022071252 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$18.03K	$18.03K	$18.03K
YoY Change	0.0%	0.0%	10.68%
Cost Of Revenue	$1.460K	$1.459K	$1.460K
YoY Change	0.0%	-0.07%
Gross Profit	$16.57K	$16.57K	$16.57K
YoY Change	0.0%	-0.02%
Gross Profit Margin	91.9%	91.88%	91.9%
Selling, General & Admin	$1.039M	$60.34K	$410.0K
YoY Change	115.07%	-85.28%	-32.31%
% of Gross Profit	6269.4%	364.25%	2474.29%
Research & Development	$634.7K	$375.8K	$70.51K
YoY Change	33.35%	432.97%
% of Gross Profit	3830.3%	2268.47%	425.53%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.674M	$965.7K	$480.5K
YoY Change	74.51%	100.98%
Operating Profit	-$1.657M	-$949.2K	-$463.9K
YoY Change	75.82%	104.59%
Interest Expense	-$6.160K	-$34.09K	$6.956M
YoY Change	-94.63%	-100.49%	286135.39%
% of Operating Profit
Other Income/Expense, Net	$280.00	-$34.09K	$0.00
YoY Change
Pretax Income	-$1.663M	-$983.2K	$6.492M
YoY Change	57.31%	-115.15%	-1124.23%
Income Tax	$0.00		$19.13K
% Of Pretax Income			0.29%
Net Earnings	-$1.663M	-$983.2K	$6.385M
YoY Change	52.74%	-115.4%	-1107.43%
Net Earnings / Revenue	-9222.57%	-5453.39%	35413.87%
Basic Earnings Per Share		-$0.49	$3.20
Diluted Earnings Per Share	-$0.52	-$0.49	$64.73K
COMMON SHARES
Basic Shares Outstanding	3.139M shares	99.40M shares	1.973M shares
Diluted Shares Outstanding		2.001M shares	1.994M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.37M	$12.33M	$11.08M
YoY Change	10.85%	11.27%	569.53%
Cash & Equivalents	$11.37M	$12.25M	$10.26M
Short-Term Investments	$3.120K	$77.94K	$820.1K
Other Short-Term Assets	$135.9K	$581.4K	$220.6K
YoY Change	-6.49%	163.55%	-29.07%
Inventory			$58.45K
Prepaid Expenses	$21.17K
Receivables
Other Receivables	$60.00K	$60.00K
Total Short-Term Assets	$11.57M	$12.91M	$11.30M
YoY Change	11.24%	14.25%	441.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.118K	$77.94K
YoY Change	-99.26%
Other Assets	$70.82K	$64.80K	$28.12K
YoY Change	15.7%	130.44%	-76.04%
Total Long-Term Assets	$70.82K	$137.1K	$88.12K
YoY Change	-19.4%	55.57%	-24.91%
TOTAL ASSETS
Total Short-Term Assets	$11.57M	$12.91M	$11.30M
Total Long-Term Assets	$70.82K	$137.1K	$88.12K
Total Assets	$11.64M	$13.05M	$11.39M
YoY Change	10.99%	14.57%	416.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$364.2K	$223.7K	$211.3K
YoY Change	-12.85%	5.85%	92.08%
Accrued Expenses	$20.13K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$436.3K	$312.2K	$283.4K
YoY Change	-10.96%	10.16%	132.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$865.8K	$883.8K	$955.9K
YoY Change	-7.69%	-7.54%
Total Long-Term Liabilities	$865.8K	$883.8K	$955.9K
YoY Change	-7.69%	-7.54%	8112.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$436.3K	$312.2K	$283.4K
Total Long-Term Liabilities	$865.8K	$883.8K	$955.9K
Total Liabilities	$1.302M	$1.196M	$1.239M
YoY Change	-8.81%	-3.49%	827.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.171M	-$5.508M
YoY Change	119.8%
Common Stock	$316.00	$314.00
YoY Change	-96.8%
Preferred Stock	$17.51M
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.34M	$11.85M	$10.15M
YoY Change
Total Liabilities & Shareholders Equity	$11.64M	$13.05M	$11.39M
YoY Change	10.99%	14.57%	416.76%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$1.663M	-$983.2K	$6.385M
YoY Change	52.74%	-115.4%	-1107.43%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$886.0K	-$1.422M	-$663.1K
YoY Change	14.49%	114.5%	136.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$6.774M
YoY Change	-100.0%	-100.0%	135371.4%
Cash From Investing Activities	$0.00	$0.00	$6.774M
YoY Change	-100.0%	-100.0%	135371.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	4.941M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-886.0K	-1.422M	-663.1K
Cash From Investing Activities	0.000	0.000	6.774M
Cash From Financing Activities	0.000	4.941M	0.000
Net Change In Cash	-886.0K	3.519M	6.110M
YoY Change	108.76%	-42.42%	-2333.28%
FREE CASH FLOW
Cash From Operating Activities	-$886.0K	-$1.422M	-$663.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41512
	dei	Entity Registrant Name EntityRegistrantName	SILO PHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3046338
	dei	Entity Address Address Line1 EntityAddressAddressLine1	560 Sylvan Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 3160
	dei	Entity Address City Or Town EntityAddressCityOrTown	Englewood Cliffs
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07632
	dei	City Area Code CityAreaCode	(718)
	dei	Local Phone Number LocalPhoneNumber	400-9031
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	SILO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3138797	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12253023	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9837001	usd
CY2022Q3	silo	Equity Investments At Cost EquityInvestmentsAtCost	77939	usd
CY2021Q4	silo	Equity Investments At Cost EquityInvestmentsAtCost	419995	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	581373	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	145324	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	12912335	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10402320	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64800	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	61210	usd
CY2022Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	72285	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	26659	usd
CY2022Q3	us-gaap	Assets Assets	13049420	usd
CY2021Q4	us-gaap	Assets Assets	10490189	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	223645	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	417937	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	16447	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72102	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72102	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	312194	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	490039	usd
CY2022Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	883807	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	937884	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	883807	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	937884	usd
CY2022Q3	us-gaap	Liabilities Liabilities	1196001	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1427923	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3138797	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3138797	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1972739	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1972739	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	314	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	197	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17361402	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12324646	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5508297	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3262577	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	11853419	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9062266	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13049420	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10490189	usd
CY2022Q3	silo	License Fees LicenseFees	18025	usd
CY2021Q3	silo	License Fees LicenseFees	18025	usd
	silo	License Fees LicenseFees	54076	usd
	silo	License Fees LicenseFees	53238	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1459	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	1459	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4378	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3544	usd
	us-gaap	Gross Profit GrossProfit	49694	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	96529	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	16566	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	16566	usd
	us-gaap	Gross Profit GrossProfit	49698	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	54943	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	323922	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	222177	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	402190	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	331419	usd
	us-gaap	Professional Fees ProfessionalFees	846617	usd
	us-gaap	Professional Fees ProfessionalFees	1273894	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	375795	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70514	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	651750	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	217962	usd
CY2022Q3	us-gaap	General Insurance Expense GeneralInsuranceExpense	30865	usd
CY2021Q3	us-gaap	General Insurance Expense GeneralInsuranceExpense	29014	usd
	us-gaap	General Insurance Expense GeneralInsuranceExpense	95023	usd
	us-gaap	General Insurance Expense GeneralInsuranceExpense	79735	usd
CY2021Q3	silo	Bad Debt Recovery Expense BadDebtRecoveryExpense	-30000	usd
	silo	Bad Debt Recovery Expense BadDebtRecoveryExpense	-20000	usd
	silo	Bad Debt Recovery Expense BadDebtRecoveryExpense	-83500	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60341	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24618	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	123084	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	141353	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	965720	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	480508	usd
	us-gaap	Operating Expenses OperatingExpenses	2020396	usd
	us-gaap	Operating Expenses OperatingExpenses	1851621	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-949154	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-463942	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1970698	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1801927	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	981	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-483	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1773	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2872	usd
	us-gaap	Other Income OtherIncome	85733	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	19082	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	6655120	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-104700	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	6655120	usd
CY2022Q3	silo	Unrealized Gain Loss On Equity Investments UnrealizedGainLossOnEquityInvestments	-35073	usd
CY2021Q3	silo	Unrealized Gain Loss On Equity Investments UnrealizedGainLossOnEquityInvestments	300876	usd
	silo	Unrealized Gain Loss On Equity Investments UnrealizedGainLossOnEquityInvestments	-256382	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.12
	silo	Unrealized Gain Loss On Equity Investments UnrealizedGainLossOnEquityInvestments	369626	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-283	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34092	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6955513	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-273859	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7040956	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-983246	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6491571	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2244557	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5239029	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19133	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19133	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-983246	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	6472438	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2244557	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	5219896	usd
CY2021Q3	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	1553	usd
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	1553	usd
CY2021Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-88872	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1163	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-229022	usd
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-87319	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1163	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-227469	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-983246	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	6385119	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2245720	usd
	us-gaap	Net Income Loss NetIncomeLoss	4992427	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1403997	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-983246	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	6385119	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2245720	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3588430	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.49
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	3.24
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.13
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.92
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.49
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.2
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.13
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.9
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.12
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2611633	usd
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.04
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2000700	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1972739	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1987170	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1871898	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2000700	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1993869	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1987170	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1893028	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9062266	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	45009	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-604072	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8503203	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15112	usd
CY2022Q2	silo	Amortization Of Prepaid Stockbased Compensation AmortizationOfPrepaidStockbasedCompensation	14124	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-658402	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7874037	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4940948	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7556	usd
CY2022Q3	silo	Amortization Of Prepaid Stockbased Compensation AmortizationOfPrepaidStockbasedCompensation	14124	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-983246	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	11853419	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1280695	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3794102	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	83728	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-930702	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	4227823	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-461990	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	3765833	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	6385119	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	10150952	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2245720	usd
	us-gaap	Net Income Loss NetIncomeLoss	4992427	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-83500	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	95925	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	83728	usd
	silo	Amortization Of Prepaid Stockbased Expense AmortizationOfPrepaidStockbasedExpense	107970	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-104700	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6655120	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-256382	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	369626	usd
	silo	Equity Shares Earned For Services EquitySharesEarnedForServices	-85733	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	19082	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1553	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	481675	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	115587	usd
	silo	Increase Decrease In Assets Of Discontinued Operation IncreaseDecreaseInAssetsOfDiscontinuedOperation	-24963	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3590	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-194292	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	84399	usd
	us-gaap	Increase Decrease In Payables To Broker Dealers IncreaseDecreaseInPayablesToBrokerDealers	16447	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-54077	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	496762	usd
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	7500	usd
	silo	Collection On Note Receivable CollectionOnNoteReceivable	20000	usd
	silo	Collection On Note Receivable CollectionOnNoteReceivable	99500	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	86707	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1504145	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	66707	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	6736070	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6843070	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3794102	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4940948	usd
	silo	Advance From A Related Party AdvanceFromARelatedParty	2366	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2366	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4940948	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3794102	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2416022	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9133027	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9837001	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1128389	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12253023	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10261416	usd
	us-gaap	Interest Paid Net InterestPaidNet	2079	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	25159	usd
	silo	Increase In Equity Investments Recorded As Deferred Revenue Pursuant To A Patent License Agree IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree	531250	usd
	us-gaap	Stock Issued1 StockIssued1	60000	usd
	silo	Asset Purchase Agreement Description AssetPurchaseAgreementDescription	On September 30, 2021, the Company entered into and closed on an Asset Purchase Agreement (the “Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company (the “Buyer”), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company’s NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form of a promissory note amounting to $60,000. The promissory note bears 8% interest per annum and matures on October 1, 2023. Accordingly, the results of operations of this component, for all periods presented, are separately reported as “discontinued operations” on the condensed consolidated statements of operations (see Note 4).
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2000700	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1993869	shares
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2245720	usd
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	2611633	usd
CY2022Q3	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	5508297	usd
CY2022Q3	silo	Working Capital WorkingCapital	12600141	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the nine months ended September 30, 2022 and year ended December 31, 2021 include the collectability of notes receivable, valuation of equity investments, estimates for obsolete and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants issued with debt and for services, and the fair value of shares and stock options issued for services and in settlements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q3	silo	Cash Spic Insured Amount CashSPICInsuredAmount	250000	usd
	us-gaap	Fdic Indemnification Asset Cash Payments Received FDICIndemnificationAssetCashPaymentsReceived	11750000	usd
CY2021	us-gaap	Fdic Indemnification Asset Cash Payments Received FDICIndemnificationAssetCashPaymentsReceived	9100000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	581373	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	145324	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	72285	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	26659	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1987170	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1987170	shares
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	375795	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70514	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	651750	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	217962	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	433429	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	368080	shares
CY2022Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-983246	usd
CY2021Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	6385119	usd
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-2245720	usd
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	3588430	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2000700	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1972739	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1871898	shares
CY2021Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	21130	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	21130	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1893028	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.2
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.8
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.78
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	419995	usd
	silo	Additionsof Equity Securities AdditionsofEquitySecurities	85733	usd
CY2021	silo	Additionsof Equity Securities AdditionsofEquitySecurities	531250	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	171407	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	359843	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-256382	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	248588	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	77939	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	419995	usd
CY2022Q3	us-gaap	Interest Rate Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net InterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet	85733	usd
	silo	Common Stock Grant Date Fair Value Per Share CommonStockGrantDateFairValuePerShare	1.1
CY2021Q3	silo	Purchase Price PurchasePrice	60000	usd
CY2021Q3	silo	Promissory Notes PromissoryNotes	60000	usd
CY2021Q3	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.08	pure
CY2021Q3	us-gaap	Long Term Debt Maturity Date LongTermDebtMaturityDate	2023-10-01
CY2021Q3	silo	Principal Balance PrincipalBalance	60000	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	58447	usd
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	58447	usd
	silo	Net Asset Of Nfid Business Disposed NetAssetOfNFIDBusinessDisposed	58447	usd
	silo	Consideration In The Form Of A Note Receivable ConsiderationInTheFormOfANoteReceivable	60000	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	1553	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	119541	usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	1079	usd
	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	98998	usd
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-1079	usd
	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	20543	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	84	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	249565	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	1553	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-1163	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-227469	usd
CY2022Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	115500	usd
CY2021Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	220000	usd
CY2021Q4	silo	Additional Notes Receivable In2021 AdditionalNotesReceivableIn2021	60000	usd
CY2022Q3	silo	Collections On Notes Receivables CollectionsOnNotesReceivables	20000	usd
CY2021Q4	silo	Collections On Notes Receivables CollectionsOnNotesReceivables	164500	usd
CY2022Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	35500	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	55500	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	60000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	60000	usd
CY2022Q3	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2018Q3	us-gaap	Investment Maturity Date InvestmentMaturityDate	2020-09-27
CY2018Q4	silo	Promissory Note Agreement PromissoryNoteAgreement	50000	usd
CY2022Q3	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.10	pure
	us-gaap	Debt Instrument Interest Rate Increase Decrease DebtInstrumentInterestRateIncreaseDecrease	0.18	pure
	silo	Received Shares ReceivedShares	10420	shares
CY2021	silo	Recovered Aggregate Bad Debt RecoveredAggregateBadDebt	7500	usd
CY2021Q2	silo	Bad Debt Recovery Cash Payment BadDebtRecoveryCashPayment	the Company and the investor, entered into a settlement agreement whereby both parties agreed to settle the remaining balance of this note receivable which was previously written off in year 2020 for a total settlement amount of $196,000 to be paid as follows; (i) an initial payment of $46,000 upon execution of the settlement agreement and (ii) $10,000 per month for fifteen months.
CY2021	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	23500	usd
CY2021	silo	Recovered Bad Debt RecoveredBadDebt	141000	usd
CY2021	us-gaap	Loans Receivable Held For Sale Reconciliation To Cash Flow Period Increase Decrease LoansReceivableHeldForSaleReconciliationToCashFlowPeriodIncreaseDecrease	196500	usd
	silo	Remains Collectible Settlement Agreement RemainsCollectibleSettlementAgreement	20000	usd
	silo	Remains Collectible Settlement Agreement Amount Reserved RemainsCollectibleSettlementAgreementAmountReserved	35500	usd
CY2021Q3	silo	Promissory Note PromissoryNote	0.08	pure
CY2021Q3	us-gaap	Investment Maturity Date InvestmentMaturityDate	2023-10-01
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	60000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	1210	usd
CY2021	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	61210	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	60000	usd
CY2022Q3	us-gaap	Interest Receivable InterestReceivable	4800	usd
	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	64800	usd
CY2022Q3	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	505000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
	silo	Warrants Term WarrantsTerm	P5Y
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15
	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	The Series C Convertible preferred stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock.
	silo	Investor Invested Amount Percentage InvestorInvestedAmountPercentage	0.50	pure
	us-gaap	Construction Contractor Liquidity Characteristic ConstructionContractorLiquidityCharacteristic	If the Company fails to file the Registration Statement or have it declared effective by the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their subscription amount, per month, until such events are satisfied.
	silo	Placement Agent Warrants Description PlacementAgentWarrantsDescription	In addition, pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.
CY2022Q3	silo	Public Offering Shares PublicOfferingShares	1000000	shares
CY2022Q3	silo	Public Offering Price Per Share PublicOfferingPricePerShare	5
CY2022Q3	silo	Purchase Of Additional Shares PurchaseOfAdditionalShares	150000	shares
CY2022Q3	silo	Purchase Of Additional Shares PurchaseOfAdditionalShares	150000	shares
	silo	Aggregate Of Converted Shares AggregateOfConvertedShares	625000	shares
CY2022Q3	us-gaap	Initial Offering Period InitialOfferingPeriod	the Company closed the Offering and issued the Shares for aggregate net proceeds of $4,940,948, after deducting underwriting discounts and commissions and offering expenses. The Company intends to use the net proceeds from the offering for research and development activities, sales and marketing, general working capital purposes, potential acquisitions of other companies, products or technologies, and to repay certain indebtedness. Concurrently with the closing of the Offering, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and conditions of the Representative’s Warrants.
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-12-26
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	pursuant to an Employment Agreement (see Note 8), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.
	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	21658	usd
CY2021Q1	silo	Purchase Agreements Description PurchaseAgreementsDescription	the Company entered into pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares of the Company’s common stock and 4,276 shares of the Company’s Series C Convertible preferred stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition, pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.
CY2022Q3	us-gaap	Initial Offering Period InitialOfferingPeriod	concurrently with the closing of the Offering as discussed above, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and conditions of the Representative’s Warrants.
CY2020Q2	silo	Employment Agreement Description EmploymentAgreementDescription	The Employment Agreement provided for a base salary of $120,000 and 152,619 of vested shares of the Company’s common stock in April 2020. In addition, Mr. Weisblum shall be eligible to earn a bonus, subject to the sole discretion of the Company’s Board of Directors (“Board”).
CY2022Q4	us-gaap	Loans Payable LoansPayable	42000	usd
CY2020Q3	silo	License Fee LicenseFee	10000	usd
CY2021Q1	silo	License Fee LicenseFee	10000	usd
	silo	Commercial Sale Term CommercialSaleTerm	P10Y
	silo	License Agreement Expire LicenseAgreementExpire	P15Y
	silo	Sublicense Income Description SublicenseIncomeDescription	The Company or Company affiliates shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product.
	silo	License Agreement Description LicenseAgreementDescription	the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b) $50,000 on or before the first anniversary of the effective date, which was paid in February 2022. The license fee is non-refundable and is not creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on February 17, 2021 and $50,000 in February 2022 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization expense of $4,375 in 2021. During the nine months ended September 30, 2022, the Company recognized amortization expense of $3,750. On December 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $15,625. On September 30, 2022, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $61,875 as reflected in the accompanying condensed consolidated balance sheets.
	silo	Schedule Of Milestone Payments ScheduleOfMilestonePayments	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 89%; text-align: left">Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">50,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Achievement of First Commercial Sale of Licensed Product</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	silo	Royalty Payments Description RoyaltyPaymentsDescription	Royalty Payments Terms: (i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and (ii)5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and
	silo	Schedule Of Umb Minimum Royalty Payments ScheduleOfUMBMinimumRoyaltyPayments	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Minimum <br/> Annual <br/> Royalty</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to First Commercial Sale</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right; width: 9%"><span style="-sec-ix-hidden: hidden-fact-171; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year of First Commercial Sale</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-172; font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First calendar year following the First Commercial Sale</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second calendar year following the First Commercial Sale</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third calendar year following the First Commercial Sale</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td> <td> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	838	usd
CY2021Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	11034	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	833	usd
CY2022Q3	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	10410	usd
	silo	Nonrefundable Cash Payment NonrefundableCashPayment	500000	usd
	silo	Net Sale Percentage NetSalePercentage	0.02	pure
	silo	Licensor Share LicensorShare	500	shares
CY2021Q1	silo	Aggregate Of Converted Shares AggregateOfConvertedShares	625000	shares
CY2021Q1	silo	Licensor Share LicensorShare	500	shares
CY2021Q1	silo	Nonrefundable Cash Payment NonrefundableCashPayment	500000	usd
CY2021Q1	silo	Revenue Term RevenueTerm	P15Y
CY2021	silo	Number Of Voting Shares NumberOfVotingShares	20000	shares
	silo	Reverse Stock Split Vote Description ReverseStockSplitVoteDescription	In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date that the Reverse Stock Split Vote is approved by Aikido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of Aikido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment.Prior to the April 12, 2021, issuance of the common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred stock which was equivalent into Aikido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of Aikido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1031250	usd
CY2022Q3	silo	Cash Received CashReceived	500000	usd
CY2022Q3	silo	Securities Received SecuritiesReceived	531250	usd
	silo	Revenue Term RevenueTerm	P15Y
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	68750	usd
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	51562	usd
CY2021	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	68750	usd
CY2021	silo	Deferred Revenue Longterm Portion Amounted DeferredRevenueLongtermPortionAmounted	893750	usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	68750	usd
CY2022Q3	silo	Deferred Revenue Longterm Portion DeferredRevenueLongtermPortion	842187	usd
	silo	Consideration Fee Payable Percentage ConsiderationFeePayablePercentage	1.10	pure
	silo	Upfront License Fees UpfrontLicenseFees	50000	usd
	silo	First Commercial Sale FirstCommercialSale	P10Y
	silo	Agreement Shall Expire AgreementShallExpire	P15Y
CY2021Q2	silo	Upfront License Fees UpfrontLicenseFees	50000	usd
	silo	Deferred Revenue Longterm Portion Amounted DeferredRevenueLongtermPortionAmounted	41620	usd
CY2021Q1	silo	Sponsored Study Agreement Description SponsoredStudyAgreementDescription	The total cost under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized the prepaid expense of $40,737.
CY2021Q2	silo	Sublicense Amount Paid SublicenseAmountPaid	342850	usd
CY2021Q2	silo	Sponsored Research Agreement Description SponsoredResearchAgreementDescription	The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement on June 15, 2021, the second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021, the third payment of $60,570 on March 1, 2022 and a fourth payment of $60,570 in August 2022, which were recorded to prepaid expense and other current assets – current to be amortized over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense.
	silo	Schedule Of Shall Pay Umb ScheduleOfShallPayUMB	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment</b></span></td> <td> </td> <td> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 4%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon execution of the July 2021 Sponsored Research Agreement</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,095</span></td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q3	silo	Company Paid Cash CompanyPaidCash	92095	usd
CY2022Q1	us-gaap	Recorded Unconditional Purchase Obligation Due In Remainder Of Fiscal Year RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear	92095	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	359021	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	215412	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	287217	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	71804	usd
CY2022Q3	silo	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	828404	usd
CY2022Q3	silo	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	828404	usd
	silo	Payment Of University PaymentOfUniversity	5000	usd
CY2021	silo	Agreement Description AgreementDescription	In 2021, the Company paid $5,000 related to this agreement. During the nine months ended September 30, 2022, the Company paid $15,000 related to this agreement.
CY2021Q4	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	1210	usd
CY2022Q3	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	4800	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	silo	Convertible Preferred Stock Value Issued ConvertiblePreferredStockValueIssued		usd
CY2021Q4	silo	Convertible Preferred Stock Value Issued ConvertiblePreferredStockValueIssued		usd
CY2022Q3	silo	Convertible Preferred Stock Value Issued1 ConvertiblePreferredStockValueIssued1		usd
CY2021Q4	silo	Convertible Preferred Stock Value Issued1 ConvertiblePreferredStockValueIssued1		usd
CY2022Q3	silo	Bad Debt Recovery Expense BadDebtRecoveryExpense		usd
CY2022Q3	us-gaap	Other Income OtherIncome		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
CY2022Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax		usd
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity		usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2022Q1	silo	Common Stock Issued For Conversion Of Series C Preferred Stock CommonStockIssuedForConversionOfSeriesCPreferredStock		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2021Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants		usd
CY2021Q2	silo	Common Stock Issued For Conversion Of Series C Preferred Stock CommonStockIssuedForConversionOfSeriesCPreferredStock		usd
	silo	Amortization Of Prepaid Stockbased Expense AmortizationOfPrepaidStockbasedExpense		usd
	silo	Equity Shares Earned For Services EquitySharesEarnedForServices		usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
	silo	Increase Decrease In Assets Of Discontinued Operation IncreaseDecreaseInAssetsOfDiscontinuedOperation		usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables		usd
	us-gaap	Increase Decrease In Payables To Broker Dealers IncreaseDecreaseInPayablesToBrokerDealers		usd
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	silo	Advance From A Related Party AdvanceFromARelatedParty		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	silo	Increase In Equity Investments Recorded As Deferred Revenue Pursuant To A Patent License Agree IncreaseInEquityInvestmentsRecordedAsDeferredRevenuePursuantToAPatentLicenseAgree		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2021Q3	silo	Finance Lease Liabilities FinanceLeaseLiabilities		usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2022Q3	silo	Additional Notes Receivable In2021 AdditionalNotesReceivableIn2021		usd
CY2022Q3	silo	Less Notes Receivable Net Current Portion LessNotesReceivableNetCurrentPortion		usd
CY2021Q4	silo	Less Notes Receivable Net Current Portion LessNotesReceivableNetCurrentPortion		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001514183

Files In Submission

Name	View Source	Status
0001213900-22-071252-index-headers.html	Edgar Link	pending
0001213900-22-071252-index.html	Edgar Link	pending
0001213900-22-071252.txt	Edgar Link	pending
0001213900-22-071252-xbrl.zip	Edgar Link	pending
f10q0922ex31-1_silopharma.htm	Edgar Link	pending
f10q0922ex31-2_silopharma.htm	Edgar Link	pending
f10q0922ex32-1_silopharma.htm	Edgar Link	pending
f10q0922ex32-2_silopharma.htm	Edgar Link	pending
f10q0922_silopharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
silo-20220930.xsd	Edgar Link	pending
silo-20220930_cal.xml	Edgar Link	unprocessable
silo-20220930_def.xml	Edgar Link	unprocessable
silo-20220930_lab.xml	Edgar Link	unprocessable
silo-20220930_pre.xml	Edgar Link	unprocessable
f10q0922_silopharma_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SILO
Silo Pharma, Inc. Stock $silo

2022 Q4 Form 10-Q Financial Statement

#000121390022071252 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILO Silo Pharma, Inc. Stock $silo

2022 Q4 Form 10-Q Financial Statement

#000121390022071252 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILO
Silo Pharma, Inc. Stock $silo